Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy
Background: In patients with dilated cardiomyopathy (DCM) and severe congestive heart failure, immunoadsorption (IA) and subsequent IgG substitution leads to an acute and prolonged hemodynamic improvement. Goal of this study was to investigate the long-term effect of immunoadsorption on morbidity. M...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2004-12, Vol.97 (3), p.517-520 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 520 |
|---|---|
| container_issue | 3 |
| container_start_page | 517 |
| container_title | International journal of cardiology |
| container_volume | 97 |
| creator | Knebel, Fabian Böhm, Marco Staudt, Alexander Borges, Adrian C. Tepper, Mirko Jochmann, Nicoline Wernicke, Klaus D. Felix, Stephan Baumann, Gert |
| description | Background: In patients with dilated cardiomyopathy (DCM) and severe congestive heart failure, immunoadsorption (IA) and subsequent IgG substitution leads to an acute and prolonged hemodynamic improvement. Goal of this study was to investigate the long-term effect of immunoadsorption on morbidity.
Methods: In a retrospective analysis of 34 patients (17 patients who have received immunoadsorption therapy and 17 control patients) were included. Inclusion criteria were DCM, left ventricular ejection fraction less than 35%, NYHA classes II–III. The average time after immunoadsorption was 3.0 years (median 2.3 years). Both groups did not differ concerning sex, age, duration of disease, medication, baseline ejection fraction and NYHA class.
Results: In patients who have received immunoadsorption (IA) the days of hospitalisation for congestive heart failure per year could be significantly reduced in contrast to the control patients (17.2 days prior to IA, 4.3 days after IA). Even if the procedural days for immunoadsorption were included there was still a significant reduction of hospitalisation if IA therapy was longer than 2.5 years ago. The days of hospitalisation increased gradually with time during the follow up period. IA induced an acute increase in EF (19.8–25.7%,
p |
| doi_str_mv | 10.1016/j.ijcard.2003.12.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67101861</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527304000063</els_id><sourcerecordid>20582184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-21f37f45d204110e075fe457dcc4cb578467968149d30854cabbb12fb9f8e18b3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EotvCP0AoF7gl9Th27FyQUAUFqVKlqly4WP6K1qskDrZDlX-Pl12pNzi9h3ne0cyD0DvADWDorg-NPxgVbUMwbhsgTYkXaAeC0xo4oy_RrmC8ZoS3F-gypQPGmPa9eI0ugLEOWkp26OeDs6vJPsxVGKopRO2tz1ult8pP0zoHZVOIy18g711USxnM1aKyd3NO1ZPP-8r6UWVnq-M5PkxbKOP99ga9GtSY3NtzXqEfX7883nyr7-5vv998vqsNhT7XBIaWD5RZgikAdpizwVHGrTHUaMYF7XjfCaC9bbFg1CitNZBB94NwIHR7hT6e9i4x_FpdynLyybhxVLMLa5IdL75E-fd_IMFMEBC0gPQEmhhSim6QS_STipsELI_y5UGe5MujfAlElii19-f9q56cfS6dbRfgwxlQyahxiGo2Pj1zXdt2VLDCfTpxrmj77V2UyRTdxlkfncnSBv_vS_4AH8ilOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20582184</pqid></control><display><type>article</type><title>Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Knebel, Fabian ; Böhm, Marco ; Staudt, Alexander ; Borges, Adrian C. ; Tepper, Mirko ; Jochmann, Nicoline ; Wernicke, Klaus D. ; Felix, Stephan ; Baumann, Gert</creator><creatorcontrib>Knebel, Fabian ; Böhm, Marco ; Staudt, Alexander ; Borges, Adrian C. ; Tepper, Mirko ; Jochmann, Nicoline ; Wernicke, Klaus D. ; Felix, Stephan ; Baumann, Gert</creatorcontrib><description>Background: In patients with dilated cardiomyopathy (DCM) and severe congestive heart failure, immunoadsorption (IA) and subsequent IgG substitution leads to an acute and prolonged hemodynamic improvement. Goal of this study was to investigate the long-term effect of immunoadsorption on morbidity.
Methods: In a retrospective analysis of 34 patients (17 patients who have received immunoadsorption therapy and 17 control patients) were included. Inclusion criteria were DCM, left ventricular ejection fraction less than 35%, NYHA classes II–III. The average time after immunoadsorption was 3.0 years (median 2.3 years). Both groups did not differ concerning sex, age, duration of disease, medication, baseline ejection fraction and NYHA class.
Results: In patients who have received immunoadsorption (IA) the days of hospitalisation for congestive heart failure per year could be significantly reduced in contrast to the control patients (17.2 days prior to IA, 4.3 days after IA). Even if the procedural days for immunoadsorption were included there was still a significant reduction of hospitalisation if IA therapy was longer than 2.5 years ago. The days of hospitalisation increased gradually with time during the follow up period. IA induced an acute increase in EF (19.8–25.7%,
p<0.01 vs. baseline).
Conclusion: IA not only leads to an acute hemodynamic improvement in patients with DCM but may also reduce morbidity in these patients during the next 3 years.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2003.12.003</identifier><identifier>PMID: 15561342</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathy, Dilated - epidemiology ; Cardiomyopathy, Dilated - therapy ; Congestive heart failure ; Digoxin - therapeutic use ; Dilated cardiomyopathy ; Diuretics - therapeutic use ; Heart ; Heart Failure - therapy ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Hospitalization ; Humans ; Immunoadsorption ; Immunosorbent Techniques ; Immunotherapy ; Male ; Medical sciences ; Middle Aged ; Morbidity ; Myocarditis. Cardiomyopathies ; Retrospective Studies ; Time</subject><ispartof>International journal of cardiology, 2004-12, Vol.97 (3), p.517-520</ispartof><rights>2004 Elsevier Ireland Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-21f37f45d204110e075fe457dcc4cb578467968149d30854cabbb12fb9f8e18b3</citedby><cites>FETCH-LOGICAL-c419t-21f37f45d204110e075fe457dcc4cb578467968149d30854cabbb12fb9f8e18b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2003.12.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16336485$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15561342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knebel, Fabian</creatorcontrib><creatorcontrib>Böhm, Marco</creatorcontrib><creatorcontrib>Staudt, Alexander</creatorcontrib><creatorcontrib>Borges, Adrian C.</creatorcontrib><creatorcontrib>Tepper, Mirko</creatorcontrib><creatorcontrib>Jochmann, Nicoline</creatorcontrib><creatorcontrib>Wernicke, Klaus D.</creatorcontrib><creatorcontrib>Felix, Stephan</creatorcontrib><creatorcontrib>Baumann, Gert</creatorcontrib><title>Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Background: In patients with dilated cardiomyopathy (DCM) and severe congestive heart failure, immunoadsorption (IA) and subsequent IgG substitution leads to an acute and prolonged hemodynamic improvement. Goal of this study was to investigate the long-term effect of immunoadsorption on morbidity.
Methods: In a retrospective analysis of 34 patients (17 patients who have received immunoadsorption therapy and 17 control patients) were included. Inclusion criteria were DCM, left ventricular ejection fraction less than 35%, NYHA classes II–III. The average time after immunoadsorption was 3.0 years (median 2.3 years). Both groups did not differ concerning sex, age, duration of disease, medication, baseline ejection fraction and NYHA class.
Results: In patients who have received immunoadsorption (IA) the days of hospitalisation for congestive heart failure per year could be significantly reduced in contrast to the control patients (17.2 days prior to IA, 4.3 days after IA). Even if the procedural days for immunoadsorption were included there was still a significant reduction of hospitalisation if IA therapy was longer than 2.5 years ago. The days of hospitalisation increased gradually with time during the follow up period. IA induced an acute increase in EF (19.8–25.7%,
p<0.01 vs. baseline).
Conclusion: IA not only leads to an acute hemodynamic improvement in patients with DCM but may also reduce morbidity in these patients during the next 3 years.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathy, Dilated - epidemiology</subject><subject>Cardiomyopathy, Dilated - therapy</subject><subject>Congestive heart failure</subject><subject>Digoxin - therapeutic use</subject><subject>Dilated cardiomyopathy</subject><subject>Diuretics - therapeutic use</subject><subject>Heart</subject><subject>Heart Failure - therapy</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immunoadsorption</subject><subject>Immunosorbent Techniques</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Retrospective Studies</subject><subject>Time</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EotvCP0AoF7gl9Th27FyQUAUFqVKlqly4WP6K1qskDrZDlX-Pl12pNzi9h3ne0cyD0DvADWDorg-NPxgVbUMwbhsgTYkXaAeC0xo4oy_RrmC8ZoS3F-gypQPGmPa9eI0ugLEOWkp26OeDs6vJPsxVGKopRO2tz1ult8pP0zoHZVOIy18g711USxnM1aKyd3NO1ZPP-8r6UWVnq-M5PkxbKOP99ga9GtSY3NtzXqEfX7883nyr7-5vv998vqsNhT7XBIaWD5RZgikAdpizwVHGrTHUaMYF7XjfCaC9bbFg1CitNZBB94NwIHR7hT6e9i4x_FpdynLyybhxVLMLa5IdL75E-fd_IMFMEBC0gPQEmhhSim6QS_STipsELI_y5UGe5MujfAlElii19-f9q56cfS6dbRfgwxlQyahxiGo2Pj1zXdt2VLDCfTpxrmj77V2UyRTdxlkfncnSBv_vS_4AH8ilOw</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Knebel, Fabian</creator><creator>Böhm, Marco</creator><creator>Staudt, Alexander</creator><creator>Borges, Adrian C.</creator><creator>Tepper, Mirko</creator><creator>Jochmann, Nicoline</creator><creator>Wernicke, Klaus D.</creator><creator>Felix, Stephan</creator><creator>Baumann, Gert</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy</title><author>Knebel, Fabian ; Böhm, Marco ; Staudt, Alexander ; Borges, Adrian C. ; Tepper, Mirko ; Jochmann, Nicoline ; Wernicke, Klaus D. ; Felix, Stephan ; Baumann, Gert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-21f37f45d204110e075fe457dcc4cb578467968149d30854cabbb12fb9f8e18b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathy, Dilated - epidemiology</topic><topic>Cardiomyopathy, Dilated - therapy</topic><topic>Congestive heart failure</topic><topic>Digoxin - therapeutic use</topic><topic>Dilated cardiomyopathy</topic><topic>Diuretics - therapeutic use</topic><topic>Heart</topic><topic>Heart Failure - therapy</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immunoadsorption</topic><topic>Immunosorbent Techniques</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Retrospective Studies</topic><topic>Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knebel, Fabian</creatorcontrib><creatorcontrib>Böhm, Marco</creatorcontrib><creatorcontrib>Staudt, Alexander</creatorcontrib><creatorcontrib>Borges, Adrian C.</creatorcontrib><creatorcontrib>Tepper, Mirko</creatorcontrib><creatorcontrib>Jochmann, Nicoline</creatorcontrib><creatorcontrib>Wernicke, Klaus D.</creatorcontrib><creatorcontrib>Felix, Stephan</creatorcontrib><creatorcontrib>Baumann, Gert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knebel, Fabian</au><au>Böhm, Marco</au><au>Staudt, Alexander</au><au>Borges, Adrian C.</au><au>Tepper, Mirko</au><au>Jochmann, Nicoline</au><au>Wernicke, Klaus D.</au><au>Felix, Stephan</au><au>Baumann, Gert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>97</volume><issue>3</issue><spage>517</spage><epage>520</epage><pages>517-520</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Background: In patients with dilated cardiomyopathy (DCM) and severe congestive heart failure, immunoadsorption (IA) and subsequent IgG substitution leads to an acute and prolonged hemodynamic improvement. Goal of this study was to investigate the long-term effect of immunoadsorption on morbidity.
Methods: In a retrospective analysis of 34 patients (17 patients who have received immunoadsorption therapy and 17 control patients) were included. Inclusion criteria were DCM, left ventricular ejection fraction less than 35%, NYHA classes II–III. The average time after immunoadsorption was 3.0 years (median 2.3 years). Both groups did not differ concerning sex, age, duration of disease, medication, baseline ejection fraction and NYHA class.
Results: In patients who have received immunoadsorption (IA) the days of hospitalisation for congestive heart failure per year could be significantly reduced in contrast to the control patients (17.2 days prior to IA, 4.3 days after IA). Even if the procedural days for immunoadsorption were included there was still a significant reduction of hospitalisation if IA therapy was longer than 2.5 years ago. The days of hospitalisation increased gradually with time during the follow up period. IA induced an acute increase in EF (19.8–25.7%,
p<0.01 vs. baseline).
Conclusion: IA not only leads to an acute hemodynamic improvement in patients with DCM but may also reduce morbidity in these patients during the next 3 years.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15561342</pmid><doi>10.1016/j.ijcard.2003.12.003</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2004-12, Vol.97 (3), p.517-520 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67101861 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Adrenergic beta-Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Cardiology. Vascular system Cardiomyopathy, Dilated - epidemiology Cardiomyopathy, Dilated - therapy Congestive heart failure Digoxin - therapeutic use Dilated cardiomyopathy Diuretics - therapeutic use Heart Heart Failure - therapy Heart failure, cardiogenic pulmonary edema, cardiac enlargement Hospitalization Humans Immunoadsorption Immunosorbent Techniques Immunotherapy Male Medical sciences Middle Aged Morbidity Myocarditis. Cardiomyopathies Retrospective Studies Time |
| title | Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T07%3A12%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduction%20of%20morbidity%20by%20immunoadsorption%20therapy%20in%20patients%20with%20dilated%20cardiomyopathy&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Knebel,%20Fabian&rft.date=2004-12-01&rft.volume=97&rft.issue=3&rft.spage=517&rft.epage=520&rft.pages=517-520&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2003.12.003&rft_dat=%3Cproquest_cross%3E20582184%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20582184&rft_id=info:pmid/15561342&rft_els_id=S0167527304000063&rfr_iscdi=true |